Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced Intensity Hematopoietic Cell Transplant for Adult Hematologic Malignancy

Reduced intensity conditioning (RIC) regimens have expanded hematopoietic cell transplantation (HCT) indications to high-risk patients who were otherwise not eligible for myeloablative regimens because of older age, extensive prior therapy, or comorbidities. RIC regimens aim to be immunoablative with limited organ and systemic toxic effects, yet enabling the graft anti-tumor effects1. Fludarabine (FLU) and cyclophosphamide (CY) have been widely used in RIC regimens, but the association between their systemic exposures and HCT outcomes are not well understood.

Source: Biology of Blood and Marrow Transplantation - May 23, 2021 Category: Hematology Authors: Takuto Takahashi, Aileen Scheibner, Qing Cao, Rachael Pearson, Kinjal Sanghavi, Daniel Weisdorf, Claudio Brunstein, John Rogosheske, Veronika Bachanova, Erica D. Warlick, Anthony Wiseman, Pamala A. Jacobson Source Type: research